These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35462108)

  • 21. Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam.
    Tosi M; Catteruccia M; Cherchi C; Mizzoni I; D'Amico A
    Acta Myol; 2022; 41(3):117-120. PubMed ID: 36349185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy.
    Lee BH; Waldrop MA; Connolly AM; Ciafaloni E
    Muscle Nerve; 2021 Aug; 64(2):153-155. PubMed ID: 33959970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series.
    Chand DH; Zaidman C; Arya K; Millner R; Farrar MA; Mackie FE; Goedeker NL; Dharnidharka VR; Dandamudi R; Reyna SP
    J Pediatr; 2021 Apr; 231():265-268. PubMed ID: 33259859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy.
    Mendell JR; Al-Zaidy SA; Lehman KJ; McColly M; Lowes LP; Alfano LN; Reash NF; Iammarino MA; Church KR; Kleyn A; Meriggioli MN; Shell R
    JAMA Neurol; 2021 Jul; 78(7):834-841. PubMed ID: 33999158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy.
    Stevens D; Claborn MK; Gildon BL; Kessler TL; Walker C
    Ann Pharmacother; 2020 Oct; 54(10):1001-1009. PubMed ID: 32204605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.
    Chand D; Mohr F; McMillan H; Tukov FF; Montgomery K; Kleyn A; Sun R; Tauscher-Wisniewski S; Kaufmann P; Kullak-Ublick G
    J Hepatol; 2021 Mar; 74(3):560-566. PubMed ID: 33186633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy.
    Schwartz M; Likhite S; Meyer K
    Drugs Today (Barc); 2021 Jun; 57(6):387-399. PubMed ID: 34151905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination molecular therapies for type 1 spinal muscular atrophy.
    Harada Y; Rao VK; Arya K; Kuntz NL; DiDonato CJ; Napchan-Pomerantz G; Agarwal A; Stefans V; Katsuno M; Veerapandiyan A
    Muscle Nerve; 2020 Oct; 62(4):550-554. PubMed ID: 32710634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec.
    Matesanz SE; Curry C; Gross B; Rubin AI; Linn R; Yum SW; Kichula EA
    J Child Neurol; 2020 Oct; 35(11):717-723. PubMed ID: 32515646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia.
    Wang T; Scuffham P; Byrnes J; Downes M
    J Neurol; 2022 Dec; 269(12):6544-6554. PubMed ID: 35980467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy.
    Kichula EA; Proud CM; Farrar MA; Kwon JM; Saito K; Desguerre I; McMillan HJ
    Muscle Nerve; 2021 Oct; 64(4):413-427. PubMed ID: 34196026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
    Dean R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Wiesner T; Malone DC; Bischof M; Toro W; Dabbous O
    J Mark Access Health Policy; 2021 Feb; 9(1):1889841. PubMed ID: 33708361
    [No Abstract]   [Full Text] [Related]  

  • 33. "The Times They Are a-Changin'." In reply to El-Zaidy et al.: AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort.
    Servais L
    J Neuromuscul Dis; 2019; 6(3):319-320. PubMed ID: 31476168
    [No Abstract]   [Full Text] [Related]  

  • 34. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
    Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
    Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
    Bitetti I; Lanzara V; Margiotta G; Varone A
    Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The respiratory impact of novel therapies for spinal muscular atrophy.
    Paul GR; Gushue C; Kotha K; Shell R
    Pediatr Pulmonol; 2021 Apr; 56(4):721-728. PubMed ID: 33098622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nusinersen improved respiratory function in spinal muscular atrophy type 2.
    Tanaka R; Fukushima F; Motoyama K; Kobayashi C; Izumi I
    Pediatr Int; 2021 Aug; 63(8):973-974. PubMed ID: 34245199
    [No Abstract]   [Full Text] [Related]  

  • 38. Treating adults with spinal muscular atrophy with nusinersen.
    Farrar MA; Kiernan MC
    J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1139. PubMed ID: 32917825
    [No Abstract]   [Full Text] [Related]  

  • 39. A severely affected adult type 2 spinal muscular atrophy patient treated with risdiplam.
    Schön M; Domingues S; Moreno T; Oliveira Santos M
    Neurol Sci; 2023 Apr; 44(4):1449-1450. PubMed ID: 36472753
    [No Abstract]   [Full Text] [Related]  

  • 40. The 4-Copy Conundrum in the Treatment of Infants with Spinal Muscular Atrophy.
    Deng S; Lee BH; Ciafaloni E; Mackenzie SJ
    Ann Neurol; 2022 Jun; 91(6):891. PubMed ID: 35338521
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.